{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":22,"n_cols":5,"rows_kept":22,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[10,2,10,3],[11,2,11,3],[14,2,14,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910459728203321"]
[null,null,"Titolo",null,"Guidelines on the Management of Latent Tuberculosis Infection [[electronic resource]]"]
[null,null,"Pubbl/distr/stampa",null,"World Health Organization, 2015"]
[null,null,"ISBN",null,"92-4-069352-1"]
[null,null,"Descrizione fisica",null,"1 online resource (38 p.)"]
[null,null,"Disciplina",null,"616.109236"]
[null,null,"Soggetti",null,"Tuberculosis -- Patients -- Treatment"]
[{"$nulls":4},"Tuberculosis -- Prevention"]
[{"$nulls":4},"Tuberculosis -- Treatment"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,"Nota di contenuto",null,"\"\"Cover\"\"; \"\"Cover\"\"; \"\"Contents\"\"; \"\"Contents\"\"; \"\"Acknowledgements\"\"; \"\"Acknowledgements\"\"; \"\"Abbreviations\"\"; \"\"Abbreviations\"\"; \"\"Declaration and management of conflict of interest\"\"; \"\"Declaration and management of conflict of interest\"\"; \"\"Executive summary\"\"; \"\"Executive summary\"\"; \"\"1. Background and process\"\"; \"\"1. Background and process\"\"; \"\"1.1. Background\"\"; \"\"1.1. Background\"\"; \"\"1.2. Scope of the guidelines\"\"; \"\"1.2. Scope of the guidelines\"\"; \"\"1.3. Target audience\"\"; \"\"1.3. Target audience\"\"; \"\"1.4. Development of the guidelines\"\"; \"\"1.4. Development of the guidelines\"\""]
[{"$nulls":4},"\"\"1.5. Quality of evidence and strength of the recommendations\"\"\"\"1.5. Quality of evidence and strength of the recommendations\"\"; \"\"2. Recommendations\"\"; \"\"2. Recommendations\"\"; \"\"2.1. Identification of at-risk populations for LTBI testing and treatment\"\"; \"\"2.1. Identification of at-risk populations for LTBI testing and treatment\"\"; \"\"2.1.1. Summary of the evidence\"\"; \"\"2.1.1. Summary of the evidence\"\"; \"\"2.1.2. Balance of benefits and harms\"\"; \"\"2.1.2. Balance of benefits and harms\"\"; \"\"2.1.3. Values and preferences of clients and health-care providers\"\""]
[{"$nulls":4},"\"\"2.1.3. Values and preferences of clients and health-care providers\"\"\"\"2.1.4. Resource considerations\"\"; \"\"2.1.4. Resource considerations\"\"; \"\"2.2. Algorithm to test and treat LTBI\"\"; \"\"2.2. Algorithm to test and treat LTBI\"\"; \"\"2.2.1. Summary of the evidence\"\"; \"\"2.2.1. Summary of the evidence\"\"; \"\"2.2.2. Balance of benefits and harms\"\"; \"\"2.2.2. Balance "]
[{"$nulls":4},"of benefits and harms\"\"; \"\"2.2.3. Values and preferences of clients and health-care providers\"\"; \"\"2.2.3. Values and preferences of clients and health-care providers\"\"; \"\"2.2.4. Resource considerations\"\"; \"\"2.2.4. Resource considerations\"\""]
[{"$nulls":4},"\"\"2.3. Treatment options for LTBI\"\"\"\"2.3. Treatment options for LTBI\"\"; \"\"2.3.1. Summary of the evidence\"\"; \"\"2.3.1. Summary of the evidence\"\"; \"\"2.3.2. Balance of benefits and harms\"\"; \"\"2.3.2. Balance of benefits and harms\"\"; \"\"2.3.3. Values and preferences of clients and health-care providers\"\"; \"\"2.3.3. Values and preferences of clients and health-care providers\"\"; \"\"2.3.4. Resource considerations\"\"; \"\"2.3.4. Resource considerations\"\"; \"\"2.4. Preventive treatment for contacts of MDR-TB cases\"\"; \"\"2.4. Preventive treatment for contacts of MDR-TB cases\"\"; \"\"2.4.1. Summary of the evidence\"\""]
[{"$nulls":4},"\"\"2.4.1. Summary of the evidence\"\"\"\"2.4.2 Balance of benefits and harms\"\"; \"\"2.4.2 Balance of benefits and harms\"\"; \"\"2.4.3. Values and preferences of clients and health-care providers\"\"; \"\"2.4.3. Values and preferences of clients and health-care providers\"\"; \"\"2.4.4. Resource considerations\"\"; \"\"2.4.4. Resource considerations\"\"; \"\"2.4.5. Conclusions\"\"; \"\"2.4.5. Conclusions\"\"; \"\"3. Issues in Implementation\"\"; \"\"3. Issues in Implementation\"\"; \"\"3.1. Adverse events monitoring\"\"; \"\"3.1. Adverse events monitoring\"\"; \"\"3.2. Risk of drug resistance following LTBI treatment\"\""]
[{"$nulls":4},"\"\"3.2. Risk of drug resistance following LTBI treatment\"\""]
[null,null,null,"Sommario/riassunto","Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active TB. A direct measurement tool for M. tuberculosis infection in humans is currently unavailable. The vast majority of infected persons have no signs or symptoms of TB but are at risk for developing activetuberculosis (TB) disease. This can be averted by preventive treatment. These Guidelines on the management of latent tuberculosis infection were developed in accordanceto the requirements and recommended p"]